The US Food and Drug Administration (FDA) has issued a draft guidance to help companies reduce animal studies of experimental drugs and adopt new methods such as computer simulations and devices that mimic human organs. The guidance suggests using non-animal testing tools when companies submit non-clinical safety data to support a drug application. The National Institutes of Health has invested $150 million in human-based research aimed at reducing the use of animal models. The revised guidance may reduce the time it takes to bring a drug to market and lower research and development costs, which can result in lower drug prices.